Episode Details

Omeros debut Q1 2026 earnings report is a blockbuster, thanks to their new drug YARTEMLEA. Approved for treating TA-TMA, it raked in $11.1 million gross revenue and $9.9 million net, already cash flow positive. Early demand is strong, with 30 accounts ordering, including 6 top 10 transplant centers. Pharmacy approvals are swift, with 60% of top 10 centers greenlit. Investors are thrilled with net income of $56.1 million, or $0.78 per share, boosted by a $73.1 million non-cash gain. Omeros pipeline is also thriving, with a $240 million upfront from Novo Nordisk and potential catalysts in Europe and late 2027 trials.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/65d76663de4d3e53